Characterize & Optimize

Expanding CRISPR-Edited Cells

Characterization and optimization are critical phases in CRISPR-mediated gene therapy development.

Determining if CRISPR edits are correctly integrated at the target locus with no off-target effects is critical. Next-generation sequencing (NGS) is a widely used method for assessing CRISPR gene editing outcomes and specificity. IDT's award-winning rhAmpSeq CRISPR Analysis System is specifically designed to analyze genome editing results. Automate DNA extraction and NGS library preparation workflows using a Beckman Coulter Life Sciences Biomek i-Series Automated Workstation to improve reproducibility and throughput in CRISPR sequencing workflows. Use the Genedata Biopharma Platform to automate analysis of sequencing data with purpose-built workflows for characterizing integration efficiency and potential off-target sites.

Determining the consequences of genome editing on cell phenotype and protein expression is essential. Confirm that cells express the gene-of-interest (GOI) as intended including appropriate protein expression levels and post-translational modifications. Optimize CRISPR-Cas modifications and protein expression if required. The SCIEX ZenoTOF 7600 System can unlock insights into protein sequence variants, peptide modifications, and post-translational modification profiles relevant to CRISPR-edited cells. Streamline characterization, including detection of post-translational modifications, sequence variants and GOI verification, using built-in mass spectrometry and NGS analysis workflows in the Genedata Biopharma Platform.

Flow cytometry can also analyze protein expression from CRISPR-edited cell populations. The Beckman Coulter Life Sciences CytoFLEX Flow Cytometer enables preclinical lab analysis. The Beckman Coulter Life Sciences CellMek SPS System can automate clinical flow cytometry sample preparation. Flow cytometry data analysis uses Beckman Coulter Life Science’s Cytobankand Kaluza C software Automate flow cytometry data analysis using the Genedata Biopharma Platform.

Optimization of guide RNA (gRNA) sequences and assay readouts requires the ability to process, manage, and interpret large, multi-modal datasets generated during gene editing workflows. Automatically capture, store and manage experimental data with the IDBS Polar Biopharma Lifecycle Management software. Data traceability is crucial, as regulatory audits necessitate secure record-keeping that documents all processes and data. The Genedata Biopharma Platform serves as a central hub for data capture, analysis and management, allowing registration of all CRISPR modifications and associated characterization results.

Explore the path toward a CRISPR platform approach